FDA starts review of Roche’s eye disease drug, setting up 2022 verdictThe FDA has started a priority review of Roche’s bispecific antibody faricimab for two major causes of blindness, Share XFDA starts review of Roche’s eye disease drug, setting up 2022 verdicthttps://pharmaphorum.com/news/fda-starts-review-of-roches-eye-disease-drug-setting-up-2022-verdict/
Allergan builds case for first drug therapy for presbyopiaIf you are in middle aged and find you have to hold your phone at arm’s length to Share XAllergan builds case for first drug therapy for presbyopiahttps://pharmaphorum.com/news/allergen-builds-case-for-first-drug-therapy-for-presbyopia/
Dopavision raises €12m for DTx to tackle myopia epidemicDigital therapeutics (DTx) startup Dopavision has raised funding to develop its lead product, an app designed to slow Share XDopavision raises €12m for DTx to tackle myopia epidemichttps://pharmaphorum.com/news/dopavision-raises-e12m-for-dtx-to-tackle-myopia-epidemic/
Roche eyes October decision by FDA for wet AMD implantThe FDA has started a review of a new implant version of Roche’s ranibizumab therapy for wet age-related Share XRoche eyes October decision by FDA for wet AMD implanthttps://pharmaphorum.com/news/roche-eyes-october-decision-by-fda-for-wet-amd-implant/
Biogen’s ambitions in gene therapy hit by another failed pivotal trialWhen Biogen acquired Nightstar Therapeutics in 2019, it added a pair inherited retinal disorder (IRD) gene therapies that Share XBiogen’s ambitions in gene therapy hit by another failed pivotal trialhttps://pharmaphorum.com/news/biogens-ambitions-in-gene-therapy-are-hit-by-a-second-failed-phase-3-trial/
Novartis halts three trials of Beovu eye drug on safety concernsProspects for Novartis’ ophthalmology drug Beovu have taken another dive after the drugmaker reported toxicity issues in a Share XNovartis halts three trials of Beovu eye drug on safety concernshttps://pharmaphorum.com/news/novartis-halts-three-trials-of-beovu-eye-drug-on-safety-concerns/
Biogen’s eye disease gene therapy fails ahead of FDA Alzheimer’s rulingBiogen has downbeat news about its gene therapy for the rare inherited eye disease, X-linked retinitis pigmentosa, announcing Share XBiogen’s eye disease gene therapy fails ahead of FDA Alzheimer’s rulinghttps://pharmaphorum.com/news/biogens-eye-disease-gene-therapy-fails-ahead-of-fda-alzheimers-ruling/
Aura raises $80m to develop its virus-like cancer drugsUS biotech Aura Biosciences has closed an oversubscribed financing, raising $80 million to help take its lead virus-like Share XAura raises $80m to develop its virus-like cancer drugshttps://pharmaphorum.com/news/aura-raises-80m-to-develop-its-virus-like-cancer-drugs/
Two biotechs target dry eye disease after Novartis’ Xiidra problemsThe pipeline for dry eye disease drugs is beginning to heat up, with two biotechs announcing key developments, Share XTwo biotechs target dry eye disease after Novartis’ Xiidra problemshttps://pharmaphorum.com/news/two-biotechs/
